122 related articles for article (PubMed ID: 9660853)
21. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6.
Denton TT; Zhang X; Cashman JR
Biochem Pharmacol; 2004 Feb; 67(4):751-6. PubMed ID: 14757175
[TBL] [Abstract][Full Text] [Related]
22. Single-dose disulfiram does not inhibit CYP2A6 activity.
Kharasch ED; Hankins DC; Baxter PJ; Thummel KE
Clin Pharmacol Ther; 1998 Jul; 64(1):39-45. PubMed ID: 9695717
[TBL] [Abstract][Full Text] [Related]
23. Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
Drug Metab Dispos; 1996 Nov; 24(11):1212-7. PubMed ID: 8937855
[TBL] [Abstract][Full Text] [Related]
24. An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver.
Sai Y; Yang TJ; Krausz KW; Gonzalez FJ; Gelboin HV
Pharmacogenetics; 1999 Apr; 9(2):229-37. PubMed ID: 10376770
[TBL] [Abstract][Full Text] [Related]
25. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4.
Kharasch ED; Hankins DC; Fenstamaker K; Cox K
Eur J Clin Pharmacol; 2000; 55(11-12):853-9. PubMed ID: 10805064
[TBL] [Abstract][Full Text] [Related]
26. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.
O'Donnell JP; Dalvie DK; Kalgutkar AS; Obach RS
Drug Metab Dispos; 2003 Nov; 31(11):1369-77. PubMed ID: 14570769
[TBL] [Abstract][Full Text] [Related]
27. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation.
Stresser DM; Kupfer D
Drug Metab Dispos; 1998 Sep; 26(9):868-74. PubMed ID: 9733665
[TBL] [Abstract][Full Text] [Related]
28. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.
Chun J; Kent UM; Moss RM; Sayre LM; Hollenberg PF
Drug Metab Dispos; 2000 Aug; 28(8):905-11. PubMed ID: 10901699
[TBL] [Abstract][Full Text] [Related]
29. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6.
Chen W; Koenigs LL; Thompson SJ; Peter RM; Rettie AE; Trager WF; Nelson SD
Chem Res Toxicol; 1998 Apr; 11(4):295-301. PubMed ID: 9548799
[TBL] [Abstract][Full Text] [Related]
30. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.
Kushida H; Fujita K; Suzuki A; Yamada M; Endo T; Nohmi T; Kamataki T
Carcinogenesis; 2000 Jun; 21(6):1227-32. PubMed ID: 10837014
[TBL] [Abstract][Full Text] [Related]
31. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1.
Duescher RJ; Elfarra AA
Arch Biochem Biophys; 1994 Jun; 311(2):342-9. PubMed ID: 8203896
[TBL] [Abstract][Full Text] [Related]
32. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor.
Chiba M; Nishime JA; Lin JH
J Pharmacol Exp Ther; 1995 Dec; 275(3):1527-34. PubMed ID: 8531125
[TBL] [Abstract][Full Text] [Related]
33. (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes.
Nunoya K; Yokoi Y; Kimura K; Kodama T; Funayama M; Inoue K; Nagashima K; Funae Y; Shimada N; Green C; Kamataki T
J Pharmacol Exp Ther; 1996 May; 277(2):768-74. PubMed ID: 8627557
[TBL] [Abstract][Full Text] [Related]
34. Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.
Ueng YF; Chen CC; Chung YT; Liu TY; Chang YP; Lo WS; Murayama N; Yamazaki H; Souček P; Chau GY; Chi CW; Chen RM; Li DT
Br J Pharmacol; 2011 Jul; 163(6):1250-62. PubMed ID: 21418183
[TBL] [Abstract][Full Text] [Related]
35. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes.
Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP
Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808
[TBL] [Abstract][Full Text] [Related]
36. In vitro metabolism of (-)-camphor using human liver microsomes and CYP2A6.
Gyoubu K; Miyazawa M
Biol Pharm Bull; 2007 Feb; 30(2):230-3. PubMed ID: 17268056
[TBL] [Abstract][Full Text] [Related]
37. Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents.
Pouyfung P; Prasopthum A; Sarapusit S; Srisook E; Rongnoparut P
Drug Metab Pharmacokinet; 2014; 29(1):75-82. PubMed ID: 23903410
[TBL] [Abstract][Full Text] [Related]
38. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
Siu EC; Tyndale RF
J Pharmacol Exp Ther; 2008 Mar; 324(3):992-9. PubMed ID: 18065502
[TBL] [Abstract][Full Text] [Related]
39. Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization.
Yano JK; Denton TT; Cerny MA; Zhang X; Johnson EF; Cashman JR
J Med Chem; 2006 Nov; 49(24):6987-7001. PubMed ID: 17125252
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
